Rua Accelerates Export Strategy, Ceases Manufacturing
Rua Bioscience announces the export-led company will cease local GMP manufacturing and accelerate its global brand strategy, building its international product pipeline while developing valuable points of difference in the areas of genetic discovery and novel product development. Working with manufacturing partners, Rua expects New Zealand patients will ultimately benefit from a wider range of affordable medicines.
Rua Releases Market Insights 2023
Rua Bioscience has released its Market Insights for 2023.
The update is designed to share information about the challenges and opportunities presented by emerging high-value medicinal cannabis markets.
Rua Signs Supply Agreement, Targets Poland and Czechia
Rua Bioscience today announced it has signed a five-year master supply agreement with Motagon to supply medicinal cannabis products to Central and Eastern European countries. Critically, the agreement gives Rua access to the emerging medicinal cannabis markets of Czechia and Poland.
Rua Bioscience Confirms First International Order
Rua Bioscience Limited (NZX: RUA) formally announced today that it has received its first order via its German distributor Nimbus Health, marking a significant commercial milestone for the export-focused company.
Significant Headway Made with Trans-Tasman Medicinal Cannabis Partnership
Rua Bioscience’s cultivation partnership with Australian-based Cann Group is making significant headway; the two companies achieving key milestones this week.
Rua signs five-year agreement with European Medicinal Cannabis Distributor Motagon
Rua Bioscience has signed an agreement with European Medicinal Cannabis Distributor, Motagon to become its preferred Australia/NZ supplier of medicinal cannabis products.
Rua receives narcotic license through Nimbus Health for distribution and marketing of our first product for Germany
Rua Bioscience Limited announced today that it has received its narcotic license through Nimbus Health GmbH for distribution and marketing of its first product for the German medicinal cannabis market – a move understood to make Rua the first medicinal cannabis company from New Zealand to take such a step.